Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trialMoshe Mittelman, Katharina Modelska, Rosemary Harrup et al.|American Journal of Hematology|2024Cited by 17
Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn StudyMoshe Mittelman, Katharina Modelska, David H. Henry et al.|Blood|2023Cited by 5